Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06144606 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: Tecartus

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]